Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 1
1960 8
1961 16
1962 21
1963 24
1964 26
1965 20
1966 11
1967 19
1968 16
1969 14
1970 9
1971 18
1972 16
1973 5
1974 10
1975 10
1976 8
1977 9
1978 13
1979 4
1980 3
1981 8
1982 3
1983 7
1984 4
1985 5
1986 9
1987 6
1988 5
1989 3
1990 8
1991 11
1992 3
1993 6
1994 7
1995 3
1996 8
1997 4
1998 5
1999 8
2000 25
2001 49
2002 71
2003 77
2004 100
2005 102
2006 135
2007 120
2008 121
2009 107
2010 119
2011 122
2012 96
2013 112
2014 115
2015 102
2016 99
2017 98
2018 100
2019 108
2020 123
2021 126
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

2,399 results
Results by year
Filters applied: . Clear all
Page 1
The Diagnosis and Treatment of Behavioral Disorders in Dementia.
Kratz T. Kratz T. Dtsch Arztebl Int. 2017 Jun 30;114(26):447-454. doi: 10.3238/arztebl.2017.0447. Dtsch Arztebl Int. 2017. PMID: 28705297 Free PMC article. Review.
Memory therapy (d = 0.47), ergotherapy (d = 0.72), music therapy (d = 0.62), and physical exercise (d = 0.68) are effective, as are antidementia drugs (galantamine: p = 0.04, donepezil: p = 0.01, rivastigmine: p = 0.02, memantine: p = 0.004). ...
Memory therapy (d = 0.47), ergotherapy (d = 0.72), music therapy (d = 0.62), and physical exercise (d = 0.68) are effective, as are antideme …
Galantamine.
Lowenthal MN. Lowenthal MN. Isr Med Assoc J. 2003 May;5(5):388. Isr Med Assoc J. 2003. PMID: 12811964 Free article. No abstract available.
Galanthamine.
Fulton B, Benfield P. Fulton B, et al. Drugs Aging. 1996 Jul;9(1):60-5; discussion 66-7. doi: 10.2165/00002512-199609010-00006. Drugs Aging. 1996. PMID: 8818586 Review.
Galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of Alzheimer's disease. Galanthamine is selective for acetylcholinesterase versus butyrylcholinesterase; however, the drug produces greater enzyme inhibition in human ery …
Galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of Alzheimer's disease. Galant …
[Galantamine].
Shimohama S. Shimohama S. Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:31-5. Nihon Rinsho. 2011. PMID: 22755151 Japanese. No abstract available.
Galantamine for vascular cognitive impairment.
Craig D, Birks J. Craig D, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004746. doi: 10.1002/14651858.CD004746.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437493 Updated. Review.
GAL-INT-6 reported sub-group data for a pure population of vascular dementia patients showing no significant differences in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog/11) and Clinician's Interview-based Impression of Change (CIBIC-plus) when …
GAL-INT-6 reported sub-group data for a pure population of vascular dementia patients showing no significant differences in Alzheimer's
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
Seltzer B. Seltzer B. Clin Interv Aging. 2010 Feb 2;5:1-6. Clin Interv Aging. 2010. PMID: 20169037 Free PMC article. Review.
An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer's disease (AD). Except for predicted differences i …
An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to in …
Galanthamine.
Cozanitis DA, Toivakka E. Cozanitis DA, et al. JAMA. 1978 Jul 14;240(2):108. doi: 10.1001/jama.240.2.108b. JAMA. 1978. PMID: 660819 No abstract available.
[Narcissus].
Miyazaki S. Miyazaki S. Chudoku Kenkyu. 2014 Mar;27(1):17-9. Chudoku Kenkyu. 2014. PMID: 24724353 Japanese. No abstract available.
Clinical pharmacokinetics of galantamine.
Farlow MR. Farlow MR. Clin Pharmacokinet. 2003;42(15):1383-92. doi: 10.2165/00003088-200342150-00005. Clin Pharmacokinet. 2003. PMID: 14674789 Review.
Galantamine is the most recently approved cholinergic drug for the treatment of Alzheimer's disease, the most common type of dementia. ...Based on the literature and clinical trial experience, galantamine appears to be an excellent treatment option for patien
Galantamine is the most recently approved cholinergic drug for the treatment of Alzheimer's disease, the most common type of d
[Galantamine].
Taéron C. Taéron C. Rev Infirm. 2008 Sep;(143):44-6. Rev Infirm. 2008. PMID: 18788671 French. No abstract available.
2,399 results